Anais brasileiros de dermatologia最新文献

{"title":"Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison","authors":"Leyla Baykal Selçuk ,&nbsp;Hande Ermiş Akkuş ,&nbsp;Burak Akşan ,&nbsp;Deniz Aksu Arıca","doi":"10.1016/j.abd.2024.05.005","DOIUrl":"10.1016/j.abd.2024.05.005","url":null,"abstract":"<div><h3>Background</h3><div>Psoriasis is a chronic inflammatory skin disease with a genetic predisposition and autoimmune component, often treated with immunomodulators such as biologic therapies.</div></div><div><h3>Objectives</h3><div>In this study, the authors evaluated the effectiveness and safety of two of these over a 52-week treatment period.</div></div><div><h3>Methods</h3><div>A double-center retrospective cohort study was conducted, enrolling patients with moderate to severe psoriasis who received either guselkumab or risankizumab at dermatology clinics for a minimum of 52-weeks.</div></div><div><h3>Result</h3><div>Out of the 90 patients enrolled in the study, 49 (54.4%) received guselkumab, while 41 (45.6%) received risankizumab. Regarding therapy efficiency, there was no statistically significant difference in PASI90 and PASI100 at week 4 between the two groups (p = 0.428, p = 0.750, respectively). By week 16, PASI90 responses were higher in the guselkumab group (p = 0.039). However, there was no difference in PASI100 response at week 16 (p = 0.957). At weeks 24 and 52, PASI90 and PASI100 responses were similar in both groups. Our results demonstrated that both guselkumab and risankizumab were effective in patients who had previously failed other biologics. Clinical outcomes in both the guselkumab and risankizumab groups had remained unaffected during prior biologic treatments, including anti-TNF, anti-IL17, and/or anti-IL12/23. Treatments yielded consistent outcomes regardless of factors such as obesity, gender, and comorbidities.</div></div><div><h3>Study limitations</h3><div>The small sample size.</div></div><div><h3>Conclusions</h3><div>Our results demonstrated that both guselkumab and risankizumab were effective in patients who had previously failed other biologics. Clinical outcomes in both the guselkumab and risankizumab groups had remained unaffected during prior biologic treatments, including anti-TNF, anti-IL17, and/or anti-IL12/23. Treatments yielded consistent outcomes regardless of factors such as obesity, gender, and comorbidities.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 2","pages":"Pages 293-299"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142963551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collagen IV immunohistochemistry and autoimmune bullous diseases: defining the location of the subepidermal bullae","authors":"Lula María Nieto-Benito ,&nbsp;Verónica Parra-Blanco ,&nbsp;Ricardo María Suárez-Fernández","doi":"10.1016/j.abd.2024.04.014","DOIUrl":"10.1016/j.abd.2024.04.014","url":null,"abstract":"","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 2","pages":"Pages 388-390"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vulvar ulcers secondary to aortic angiosarcoma in a patient with misdiagnosed cancer of unknown primary origin⋆","authors":"Denis Miyashiro ,&nbsp;Regina Barros Domingues ,&nbsp;Malu Viter da Rosa Barbosa ,&nbsp;Claudia Giuli Santi ,&nbsp;Marcello Menta Simonsen Nico ,&nbsp;José Antonio Sanches","doi":"10.1016/j.abd.2024.07.008","DOIUrl":"10.1016/j.abd.2024.07.008","url":null,"abstract":"","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 2","pages":"Pages 384-387"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical presentation of Schwannoma mimicking squamous cell carcinoma","authors":"Pedro Rolo de Matos ,&nbsp;Miguel Silva ,&nbsp;Gilberto Rosa ,&nbsp;Pedro Canão ,&nbsp;Filomena Azevedo","doi":"10.1016/j.abd.2024.07.011","DOIUrl":"10.1016/j.abd.2024.07.011","url":null,"abstract":"","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 2","pages":"Pages 360-362"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143027930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linear IgA bullous dermatosis: 32 years of experience","authors":"Tugba Atci ,&nbsp;Gizem Pehlivan Ulutas ,&nbsp;Ecem Güreler Sirkeci ,&nbsp;Rıfkiye Küçükoğlu","doi":"10.1016/j.abd.2024.03.015","DOIUrl":"10.1016/j.abd.2024.03.015","url":null,"abstract":"<div><h3>Background</h3><div>Linear IgA bullous dermatosis (LABD) is an uncommon disease with only a few reported studies in large series with long follow-up periods.</div></div><div><h3>Objectives</h3><div>To evaluate the clinical presentation, immunopathological features, management, and disease course in LABD patients.</div></div><div><h3>Methods</h3><div>Data including demographics, clinical features, histopathological and immunofluorescence findings of LABD patients, in addition to the preferred treatments and responses to treatments were evaluated.</div></div><div><h3>Results</h3><div>Among 26 patients diagnosed with LABD, 17 (65.4%) were female. The mean age was 40.3 ± 22.4 (6‒80) years of whom 21 were adults. The most common mucosal involvement was oral (n = 9, 34.6%). Continuous linear IgA deposition was present on the basement membrane zone of all patients in addition to C3 (n = 13), IgG (n = 9), IgM (n = 4), and fibrinogen (n = 4). Three patients were lost to follow-up without any treatment. Dapsone was the treatment of choice in most (n = 21, 91.3%) patients in addition to systemic corticosteroids (n = 17), azathioprine (n = 3), tetracycline and nicotinamide (n = 2). Complete and partial remissions were achieved in 11 (47.8%) and 12 (52.2%) patients, respectively, in a mean follow-up period of 45.9 ± 43.9 (3‒158) months. Furthermore, 17 patients were still under treatment at the end of the follow-up period.</div></div><div><h3>Study limitations</h3><div>Retrospective study conducted in a single center.</div></div><div><h3>Conclusions</h3><div>LABD may occur at two separate peaks, one in the second and the other in the sixth decade of life with a female predominance. Other immunoglobulins may be associated with dominant IgA antibody deposition and the most commonly used therapeutic option for LABD patients was oral dapsone.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 2","pages":"Pages 277-282"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142811939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid","authors":"Guirong Liang ,&nbsp;Hua Qian ,&nbsp;Chao Sun ,&nbsp;Hanmei Zhang ,&nbsp;Zhiliang Li ,&nbsp;Suo Li ,&nbsp;Ke Jing ,&nbsp;Chenjing Zhao ,&nbsp;Yuan Wang ,&nbsp;Ruiyu Xiang ,&nbsp;Xiaoguang Li ,&nbsp;Suying Feng","doi":"10.1016/j.abd.2024.04.012","DOIUrl":"10.1016/j.abd.2024.04.012","url":null,"abstract":"<div><h3>Background</h3><div>Conventional systemic corticosteroid therapy for bullous pemphigoid (BP) has been challenged due to severe adverse events. Dupilumab has emerged as an alternative therapeutical option of BP patients.</div></div><div><h3>Objectives</h3><div>To evaluate the efficacy of dupilumab monotherapy and the combination with medium/low-dose corticosteroids for BP treatment.</div></div><div><h3>Methods</h3><div>Thirteen, twenty-four and thirty-two BP patients treated with Dupilumab monotherapy (Dupi group), dupilumab combined with corticosteroids (Dupi + CS group), and corticosteroid monotherapy (CS group), respectively, were retrospectively analyzed for various clinical and laboratory parameters.</div></div><div><h3>Results</h3><div>In the Dupi group, the total Bullous Pemphigoid Disease Area Index (BPDAI) Total, Erosion/Blister, Urticaria/Erythema and Itching NRS scores were all reduced significantly after 2–4 weeks of treatment, but the BPDAI Mucosal Score was not changed significantly at the end of the overextended time of treatment. All the above clinical parameters and many laboratory parameters (including the serum anti-BP180 autoantibodies [IgG] level, blood eosinophil count, and percentage) were significantly reduced in both Dupi + CS and CS groups after treatment, but no statistical differences were found in the reduction rates of these parameters between the two groups. However, the Dupi + CS group had less baseline dose and cumulative dosage of prednisone at the time of disease control, and fewer adverse effects were reported than the CS group.</div></div><div><h3>Study limitations</h3><div>The retrospective design and small clinical sample size of the Dupi group.</div></div><div><h3>Conclusions</h3><div>For BP patients, dupilumab monotherapy based on the treatment of atopic dermatitis can significantly improve skin lesions and pruritus symptoms but may be ineffective for oral mucosal lesions. The combination of dupilumab and medium/low-dose corticosteroids can achieve the same effect of corticosteroid therapy with superior safety.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 2","pages":"Pages 243-252"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil","authors":"Tania F. Cestari ,&nbsp;Cacilda da Silva Souza ,&nbsp;Luna Azulay-Abulafia ,&nbsp;Ricardo Romiti ,&nbsp;André V.E. Carvalho ,&nbsp;Caio César Silva de Castro ,&nbsp;Sílvio Alencar Marques ,&nbsp;João Roberto Antonio ,&nbsp;Lincoln Fabrício ,&nbsp;Ahmed M. Soliman ,&nbsp;Tianshuang Wu ,&nbsp;Ranjeeta Sinvhal ,&nbsp;Vassilis Stakias ,&nbsp;Alexandra P. Song ,&nbsp;Jasmina Kalabic ,&nbsp;Naomi Martin ,&nbsp;Luiza Keiko Matsuka Oyafuso","doi":"10.1016/j.abd.2024.08.002","DOIUrl":"10.1016/j.abd.2024.08.002","url":null,"abstract":"<div><h3>Background</h3><div>Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit.</div></div><div><h3>Objective</h3><div>The authors assessed the efficacy and safety of risankizumab compared with methotrexate in adults with moderate-to-severe plaque psoriasis.</div></div><div><h3>Methods</h3><div>IMMbrace was a phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study. Patients received subcutaneous risankizumab 150 mg at weeks 0, 4, and 16 plus oral placebo weekly, or oral methotrexate 5 mg weekly (with dose escalation up to 25 mg based on response and tolerability) plus subcutaneous placebo at weeks 0, 4, and 16. Primary efficacy endpoints were the proportions of patients who achieved ≥ 90% improvement in Psoriasis Area and Severity Index (PASI90) and static Physician’s Global Assessment of clear/almost clear (sPGA 0/1) at week 28. Safety was also assessed.</div></div><div><h3>Results</h3><div>Among 98 patients randomized (risankizumab, n = 50; methotrexate, n = 48), 95 completed the double-blind period. At week 28, significantly higher proportions of patients treated with risankizumab versus methotrexate achieved PASI90 (84.0% vs. 35.4%; p &lt; 0.001); sPGA 0/1 was achieved by 90.0% and 64.6% of patients in the risankizumab and methotrexate groups (p ≤ 0.001). Risankizumab efficacy was maintained throughout week 112. Adverse event rates were similar in the two groups.</div></div><div><h3>Study limitations</h3><div>The sample size was small due to the difficulty of recruiting patients without methotrexate use.</div></div><div><h3>Conclusions</h3><div>Risankizumab demonstrated superior efficacy over methotrexate at week 28; efficacy was maintained, and no new safety findings were observed through week 112.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 2","pages":"Pages 260-271"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of eosinophilic cellulitis with a short course of Dupilumab","authors":"Hiram Larangeira de Almeida Junior ,&nbsp;Ana Letícia Boff","doi":"10.1016/j.abd.2024.07.010","DOIUrl":"10.1016/j.abd.2024.07.010","url":null,"abstract":"","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 2","pages":"Pages 401-403"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First case of Trichophyton indotineae in Brazil: clinical and mycological criteria and genetic identification of terbinafine resistance.","authors":"John Verrinder Veasey, Renata Diniz Jacques Gonçalves, Guilherme Camargo Julio Valinoto, Gustavo de Sá Menezes Carvalho, Giovanna Azevedo Celestrino, Ana Paula Carvalho Reis, Ana Paula Cordeiro Lima, Antonio Charlys da Costa, Marcia de Souza Carvalho Melhem, Gil Benard, Maria Gloria Teixeira Sousa","doi":"10.1016/j.abd.2025.01.001","DOIUrl":"https://doi.org/10.1016/j.abd.2025.01.001","url":null,"abstract":"","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143497944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Profile of dermatoses in extreme weather events: case series during floods in the state of Rio Grande do Sul, Brazil.","authors":"Analupe Webber, Cíntia Cristina Pessin, Gabriela Agne Magnus, Guilherme Ladwig Tejada, Isadora da Rosa Hoefel, Jacqueline Sarmento Fernandes, Juliana Catucci Boza, Juliano Peruzzo, Marcelo Balbinot Lucca, Mariele Bevilaqua, Monica Zechmeister Berg, Nathália Hoffmann Guarda Aguzzoli, Renata Alves Sanseverino, Rosemarie Mazzuco, Taciana Dal'Forno Dini, Vanessa Santos Cunha, Veronica Hamann Aita, Renan Rangel Bonamigo","doi":"10.1016/j.abd.2024.12.001","DOIUrl":"https://doi.org/10.1016/j.abd.2024.12.001","url":null,"abstract":"<p><strong>Background: </strong>The skin is the first organ of the human body to be exposed to flood water, with local and possibly systemic consequences. There are no Brazilian data on dermatological diseases during recent climate catastrophes related in the country.</p><p><strong>Objectives: </strong>To assess the demographic profile and dermatological diagnoses in people displaced from their homes and sheltered in collective housing and among rescue workers during the extreme climate crisis in the state of Rio Grande do Sul, Brazil, in 2024.</p><p><strong>Methods: </strong>This was a cross-sectional and observational study. Information was collected in person or through records, retrospectively.</p><p><strong>Results: </strong>Data were collected from 371 people with dermatological complaints, and a total of 423 dermatoses were diagnosed. The most prevalent dermatological diseases were dermatoparasitosis, pyoderma, and skin conditions due to trauma and/or injuries. The male gender was statistically associated with traumatic dermatoses/injuries, and females with pyoderma (p < 0.05).</p><p><strong>Conclusion: </strong>In the recent episode of extreme climate crisis in Brazil, infectious and traumatic dermatoses were the most prevalent among the affected persons. The role of dermatologists in providing care for this population, as well as guiding other colleagues in the management of skin diseases during the floods is highlighted.</p><p><strong>Study limitations: </strong>The study was conducted in shelters, and some data were evaluated retrospectively. No complementary exams were used for diagnosis.</p>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}